ISPE Issues Drug Shortage Survey
FOR IMMEDIATE RELEASE
Contact:
Danielle Hould
ISPE Communications Manager
Tel: +1-813-960-2105, ext. 277
Fax: +1 813.264.2816
dhould@ispe.org
www.ISPE.org
ISPE Drug Shortage Initiative Issues Survey in
Support of Global Efforts to Understand Drug Shortages
(TAMPA, FLORIDA, USA, 14 February 2013) – ISPE, the International Society
for Pharmaceutical Engineering, announced today it will conduct a global survey on drug shortages that will
be sent directly to its international Membership in mid-February. As a not-for-profit association with both
industry and regulator Members in 90 countries, ISPE is uniquely positioned to facilitate communication
between the different sectors of the pharmaceutical industry and global health authorities as they seek to
address this complex problem. The survey goal is to leverage ISPE Members’ expertise to gather data on the
technical, scientific, manufacturing, quality and compliance issues that have resulted in drug shortages.
Preliminary results are expected in June 2013.
“The prevention of drug shortages is critically important to global health,” said Nancy S. Berg, ISPE
President and CEO. “Any effort to effectively address the complex and multi-faceted issues contributing to
drug shortages requires close technical collaboration and clear communication between the pharmaceutical
industry and global health authorities. ISPE is committed to supporting efforts to uncover the root causes of
drug shortages, and we believe this survey is a critical first step.”
The survey was developed by ISPE’s Drug Shortage Initiative, led by a task force of industry leaders with
review and input by leading global health authorities and related organizations. By design, the task force
has limited the scope of this survey to the technical, scientific, manufacturing, quality and compliance
issues that have resulted in drug shortages. Survey responses will be completely anonymous, and all data will
be tabulated by a third-party firm.
ISPE’s goal in collecting this survey data is to provide the pharmaceutical industry and health
authorities with much-needed scientific data to support the development of risk-based approaches, using
modern quality systems, to mitigate and prevent drug shortages. ISPE also plans to leverage its international
network to lead collaboration between regulators and industry regarding drug shortages through meetings,
conferences and industry groups like the International Leadership Forum.
For more information on this important initiative, please visit www.ISPE.org/DrugSurveyDetails.
About ISPE
ISPE, the International Society for Pharmaceutical Engineering, is the world’s largest
not-for-profit association serving its Members through leading scientific, technical and regulatory
advancement throughout the entire pharmaceutical lifecycle. The 20,000 Members of ISPE are building solutions
in the development and manufacture of safe and effective pharmaceutical and biologic medicines and medical
delivery devices in more than 90 countries around the world. Founded in 1980, ISPE has its worldwide
headquarters in Tampa, Florida, USA and offices in Brussels, Belgium, Singapore and Shanghai, China. Visit www.ISPE.org for more information.
###